查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552895

癌症生物标记市场规模、份额、趋势分析报告：按类型、生物分子、应用、技术、地区和细分市场预测，2024-2030

Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Prostate Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, By Technology, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

癌症生物标记市场成长与趋势

根据Grand View Research, Inc.最新报告显示，到2030年，全球癌症生物标记市场规模预计将达到697.6亿美元，预计2024年至2030年复合年增长率为12.7%。

由于针对新型癌症生物标记的药物开发的开创性倡议，加上技术先进的伴同性诊断试剂套件的采用，预计该市场具有很高的成长潜力。提高患者对个人化医疗的认识也有望支持癌症生物标记的采用。

此外，政府积极努力开发新的癌症诊断技术也是促进市场成长的关键因素。例如，美国国家癌症美国(NCI) 资助了超过八个与癌症生物标记开发相关的研究领域。英国癌症研究中心、肺癌研究基金会和美国国立卫生研究院是资助生物标记研究的组织之一。

据报道，大量饮酒、吸烟、有不健康饮食习惯和久坐生活方式的人患癌症的风险比其他人高 80%。人类乳突病毒 (HPV)、 EB病毒、B型肝炎病毒和幽门螺旋桿菌等感染疾病也被研究与癌症的发生有关。

癌症生物标记市场报告亮点

  • 收益而言，到 2023 年，乳癌细分市场将占据重要的市场占有率，预计在预测期内复合年增长率将达到最快。
  • 其他细分市场将在 2023 年增长，这与罕见癌症研究的增加、基因组学和蛋白​​质组学的进步、胰腺癌和卵巢癌等癌症发病率的上升以及对个性化医疗的需求不断增长有关，占据了显着的份额。
  • 以 2023 年收益占有率计算，遗传生物标记细分市场占据主导地位。由于多种驱动因素​​，遗传生物标记在癌症生物标记市场中至关重要。
  • 表观遗传学领域是预测期内成长最快的领域。推动该领域成长的关键因素之一是新型生物标记开发研究的扩展。
  • 就 2023 年的收益占有率而言，诊断细分市场占据主导地位。高效且有效的肿瘤测试特异性癌症生物标记的开发进展以及政府倡议的增加可能会支持该领域的成长。
  • 个人化医疗领域是预测期内成长最快的领域。
  • 成像技术领域因其在生物标记发现和诊断方面的高性能、准确性和广泛适用性，在 2023 年占据了市场占有率。
  • 北美在癌症生物标记市场占据主导地位，2023 年销售份额为 43.84%。这一优势是由于存在大量专门研究癌症生物标记的市场参与企业，以及美国政府在促进创新的研发方面的大量投资。
  • 预计亚太地区癌症生物标记市场在预测期内将以 14.3% 的复合年增长率增长最快。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章癌症生物标记市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌症生物标记市场分析工具
    • 波特的分析
    • PESTEL分析

第四章癌症生物标记市场：按类型估计和趋势分析

  • 细分仪表板
  • 癌症生物标记市场：类型变异分析，2023 年和 2030 年
  • 乳癌
  • 摄护腺癌
  • 大肠直肠癌
  • 子宫颈癌
  • 肝癌
  • 肺癌
  • 其他的

第五章癌症生物标记市场：生物分子的估计与趋势分析

  • 细分仪表板
  • 癌症生物标记市场：生物分子变异分析，2023 年和 2030 年
  • 基因生物标记
  • 表观遗传学生物标记物
  • 代谢生物标记
  • 蛋白质体生物标记
  • 其他的

第六章癌症生物标记市场：按应用、估计和趋势分析

  • 细分仪表板
  • 癌症生物标记市场：2023 年和 2030 年应用变化分析
  • 药物发现与开发
  • 诊断
  • 个人化医疗
  • 其他的

第七章癌症生物标记市场：技术估计和趋势分析

  • 细分仪表板
  • 癌症生物标记市场：2023 年和 2030 年技术变化分析
  • 成像技术
  • 体学

第八章癌症生物标记市场：按地区估计和趋势分析

  • 2023 年和 2030 年癌症生物标记市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc
    • Affymetrix Inc
    • Illumina, Inc.
    • Agilent Technologies
    • F. Hoffmann-La Roche AG
    • Merck &Co. Inc
    • Hologic, Inc
    • Sino Biological Inc
简介目录
Product Code: GVR-1-68038-862-6

Cancer Biomarkers Market Growth & Trends:

The global cancer biomarkers market size is expected to reach a value of USD 69.76 billion by 2030 and is anticipated to expand at a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

Cancer Biomarkers Market Report Highlights:

  • The breast cancer segment held a significant market share in terms of revenue in 2023 and it is also expected to be the witness the fastest CAGR over the forecast period.
  • The others segment held a notable share in 2023 pertaining to the increased research on rare cancers, advancements in genomics and proteomics, the rising incidence of cancers such as pancreatic and ovarian, and the growing demand for personalized medicine.
  • The genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial in the cancer biomarkers market due to several driving factors.
  • The epigenetics segment is expected to be the fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is the growing research for the development of novel biomarkers.
  • The diagnostics segment dominated the market in terms of revenue share in 2023. Factors such as the growing development of cancer biomarkers based on oncology tests that are highly efficient and effective and growing government initiatives may drive the segment's growth.
  • The personalized medicine segment is the fastest growing segment during the forecast period.
  • The imaging technologies segment dominated the market share in 2023 due to its high-throughput nature, accuracy, and broad applicability in biomarker discovery and diagnosis.
  • North America dominated the cancer biomarkers market with revenue share of 43.84% in 2023. This dominance is due to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, which foster innovation.
  • Asia Pacific cancer biomarkers market is anticipated to witness the fastest growth at a CAGR of 14.3% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cancer Biomarkers Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cancer Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Biomarkers Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Breast Cancer
    • 4.3.1. Breast Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Prostate Cancer
    • 4.4.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Colorectal Cancer
    • 4.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cervical Cancer
    • 4.6.1. Cervical Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Liver Cancer
    • 4.7.1. Liver Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Lung Cancer
    • 4.8.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Biomarkers Market: Biomolecule Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Biomarkers Market: Biomolecule Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Genetic Biomarkers
    • 5.3.1. Genetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Epigenetic Biomarkers
    • 5.4.1. Epigenetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Metabolic Biomarkers
    • 5.5.1. Metabolic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Proteomic Biomarkers
    • 5.6.1. Proteomic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cancer Biomarkers Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Drug Discovery and Development
    • 6.3.1. Drug Discovery and Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Diagnostics
    • 6.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Personalized Medicine
    • 6.5.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Biomarkers Market: Technology Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cancer Biomarkers Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Imaging Technology
    • 7.3.1. Imaging Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. OMICS
    • 7.4.1. OMICS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cancer Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Cancer Biomarkers Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. South Korea Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Abbott
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. QIAGEN
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Thermo Fisher Scientific Inc
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Affymetrix Inc
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Illumina, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Agilent Technologies
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. F. Hoffmann-La Roche AG
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Merck & Co. Inc
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Hologic, Inc
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Sino Biological Inc
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives